Inclusion Criteria:  18 years old≤Age≤75 years old, male or female; Diagnosis of granulomatosis with polyangiitis(GPA) or microscopic polyangiitis(MPA)； Newly diagnosed or relapsed GPA or MPA that requires treatment with cyclophosphamide(CYC) and glucocorticoids(GCs)； Positive test for anti-proteinase 3(PR3) or anti-myeloperoxidase (MPO)； Estimated glomerular filtration rate ≥20 mL/minute/1.73 m^2； At least 1 major item, or at least 3 non-major items, or at least the 2 renal items on BVAS；  Exclusion Criteria:  Active or latent tuberculosis infection; Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage requiring pulmonary ventilation support, rapid-onset mononeuritis multiplex or central nervous system involvement； Any other multi-system autoimmune disease； Positive test for HBsAg or HBcAb； Received CYC within 6 months before the first administration or Received rituximab(RTX) within 12 months before the first administration； Received glucocorticoid shock therapy within 4 weeks before the first administration； Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously before the first administration； Received a anti-tumor necrosis factor treatment, any other experimental or biological therapy, intravenous immunoglobulin (Ig) or plasma exchange, antithymocyte globulin, required renal dialysis or kidney transplant within 12 weeks before the first administration； Pregnant or lactating.